Dr. Daniel Kuritzkes, MD

• Infectious Disease Medicine

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Harvard Medical School

  Medical School, 1983

• English

• Creole

• French Creole

• Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity, 2016-10-14

• HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naive Men and Women in the United States, 2016-03-19

• Delaying a Treatment Switch in Antiretroviral-Treated HIV Type 1-Infected Patients with Detectable Drug-Resistant Viremia Does Not Have a Profound Effect on Immune Parameters: AIDS Clinical Trials Group Study A5115, 2009-09-24

• Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration, 2017-07-05

• Instantaneous Inhibitory Potential is Similar to Inhibitory Quotient at Predicting HIV-1 Response to Antiretroviral Therapy, 2010-07-01

• Viremic Control and Viral Coreceptor Usage in Two HIV-1-Infected Persons Homozygous forCCR5?32, 2015-05-15

• Treatment-Mediated Alterations in HIV Fitness Preserve CD4+T Cell Counts but Have Minimal Effects on Viral Load, 2010-11-24

• Antiretroviral-Free HIV-1 Remission and Viral Rebound Following Allogeneic Stem Cell Transplantation: A Report of Two Cases, 2014-09-02

• Virologic Response, Early HIV-1 Decay and Maraviroc Pharmacokinetics with the Nucleos(t)ide-free Regimen of MaravIroc plus Darunavir/ritonavir in a Pilot Study, 2013-10-01

• Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study, 2017-11-22

• Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen, 2005-04-12

• A Phase III Comparative Study of the Efficacy and Tolerability of Three Non-Nucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers: A Randomized, Controlled Trial, 2014-10-07

• Nanoplasmonic Quantitative Detection of Intact Viruses from Unprocessed Whole Blood, 2013-05-20

• Relationship between Minority NNRTI Resistance Mutations, Adherence, and the Risk of Virologic Failure, 2012-01-14

• Emerging nanotechnology approaches for HIV/AIDS treatment and prevention, 2010-02-25

• Rapid, label-free CD4 testing using a smartphone compatible device, 2017-08-22

• Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide, 2008-08-15

• SARS-CoV-2 viral load is associated with increased disease severity and mortality, 2020-10-30

• Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines, 2020-02-05

• Outcomes After Virologic Failure of First-line ART in South Africa, 2010-04-24

• Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy, 2014-03-06

• ACTG 5197: A Placebo Controlled Trial of Immunization of HIV-1 Infected Persons with a Replication Deficient Ad5 Vaccine Expressing the HIV-1 Core Protein, 2010-09-01

• Immunological and Neurometabolite Changes associated with switch from Efavirenz to an Integrase Inhibitor, 2019-08-15

• Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211, 2009-03-01

• Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption, 2017-11-27

• Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095, 2010-03-01

• Crosstalk between Host Genome and Metabolome among People with HIV in South Africa, 2022-07-06

• Enumeration of CD4+T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients, 2011-07-06

• Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update, 2009-03-06

• Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262), 2011-11-13

• Low-Level Detection and Quantitation of Cellular HIV-1 DNA and 2-LTR Circles Using Droplet Digital PCR, 2012-09-04

• Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation, 2018-05-10

• DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics, 2018-10-16

• Tropism Testing in the Clinical Management of HIV-1 Infection, 2010-05-13

• The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates, 2010-06-25

• Drug Resistance in HIV-1, 2011-11-21

• HIV-1 proviral landscape characterization varies by pipeline analysis, 2021-07-08

• Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana, 2018-05-29

• Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning, 2020-11-23

• Immune correlates of HIV-1 reservoir cell decline in early-treated infants, 2022-07-19

• Determination of RNA structural diversity and its role in HIV-1 RNA splicing, 2020-05-06

• Prevention of HIV-1 Transmission with Post-Exposure Prophylaxis after Inadvertent Infected Blood Transfusion, 2014-06-19

• Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure, 2010-03-01

• Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV, 2017-10-06

• Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa, 2022-01-12

• Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa, 2012-03-13

• Recommendations on data sharing in HIV drug resistance research, 2023-09-22

• Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist TherapyIn Vivo, 2009-05-25

• The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation, 2010-11-04

• Response to Vicriviroc in Treatment-Experienced Subjects Using an Enhanced Sensitivity Co-receptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211, 2009-12-01

• Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases, 2012-03-28

• Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure, 2011-02-24

• High rate of K65R for ART naive patients with subtype C HIV infection failing a TDF-containing first-line regimen in South Africa, 2012-08-24

• Treatment options after virological failure of first line tenofovir-based regimens in South Africa: an analysis by deep sequencing, 2016-04-24

• Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV, 2016-04-27

• SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses, 2011-12-02

• Mother-to-Child HIV Transmission within uteroDolutegravir vs. Efavirenz in Botswana, 2020-07-01

• Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy, 2015-10-02

• The Future of HIV Treatment, 2012-08-01

• Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV, 2021-05-01

• Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa, 2012-09-28

• XMRV Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions, 2010-10-11

• A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors, 2009-10-08

• Development of a microfluidic system for measuring HIV-1 viral load, 2010-05-05

• Relationship of HIV Reservoir Characteristics with Immune Status and Viral Rebound Kinetics in an HIV Therapeutic Vaccine Study, 2014-11-28

• Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b), 2015-11-28

• Efficient on-chip isolation of HIV subtypes, 2012-03-06

• Postpartum Antiretroviral Drug Resistance in HIV-1-infected Women Receiving Pregnancy-Limited Antiretroviral Therapy, 2010-01-02

• Motion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone, 2018-05-16

• Drug Resistance and Viral Tropism in HIV-1 Subtype C-Infected Patients in KwaZulu-Natal, South Africa: Implications for Future Treatment Options, 2011-11-01

• The Size of the Expressed HIV Reservoir Predicts Timing of Viral Rebound after Treatment Interruption, 2016-01-28

• HIV-1 Entry Inhibitors: Recent Development and Clinical Use, 2013-01-03

• Is France Once Again Looking for a Scapegoat?, 2021-12-29

• Acute On-Chip HIV Detection Through Label-Free Electrical Sensing of Viral Nano-Lysate, 2013-02-27

• Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate, 2010-12-01

• HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study, 2017-11-07

• Quantum dot-based HIV capture and imaging in a microfluidic channel, 2009-06-18

• Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C, 2012-09-03

• Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia, 2011-03-13

• Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment, 2009-01-15

• Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets, 2015-03-06

• COVID-19 and HIV infection co-pandemics and their impact: a review of the literature, 2021-05-05

• Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials, 2016-07-01

• Adaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images, 2021-06-10

• 38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality, 2021-12-04

• Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19, 2021-12-20

• Patients Infected with CRF07_BC Have Significantly Lower Viral Loads than Patients with HIV-1 Subtype B: Mechanism and Impact on Disease Progression, 2014-12-11

• Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1gagVaccine Trial, 2012-03-30

• Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL, 2012-11-15

• Incomplete Adherence to Antiretroviral Therapy is Associated with Higher Levels of Residual HIV-1 Viremia, 2014-01-14

• Evaluation of HIV-1 Ambiguous Nucleotide Frequency during Antiretroviral Treatment Interruption, 2012-09-01

• "Cure” versus "Clinical Remission”: The impact of a medication description on the willingness of people living with HIV to take a medication., 2020-04-21

• Rapid automated cell quantification on HIV microfluidic devices†, 2009-09-30

• Paper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens†, 2017-02-02

• Low Uptake of Antiretroviral Therapy and High Mortality After Tuberculosis or Opportunistic Infection in KwaZulu-Natal, South Africa, 2011-10-11

• Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation, 2017-07-28

• Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva, 2015-06-05

• Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile, 2019-11-27

• Resistance in Pediatric Patients Experiencing Virologic Failure with First- and Second-Line Antiretroviral Therapy, 2013-12-25